ANGO

SEC source: 0001567619-20-007647 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 256,173

F1 · shares: The exempt disposition of 4,245 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on April 4, 2016.

SEC source: 0001567619-20-004259 · doc1.xml · nonDerivative · entry 1

Boucher Brent J. · CIK 0001766229 · SVP and GM of Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,416

F1 · shares: The exempt disposition of 490 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on February 12, 2018.

SEC source: 0001567619-20-002340 · doc1.xml · derivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP, General Counsel and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,204

Underlying: Common Stock · 18,204 shares

Expires 2030-02-03

F2 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on February 3, 2021, such that 25% of the options will vest on each of February 3, 2021, 2022, 2023 and 2024.

SEC source: 0001567619-20-002340 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP, General Counsel and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,499

F1 · shares: This acquisition of 5,376 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 5,376 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on February 3, 2021, such that 25% of the restricted stock units will vest on each of February 3, 2021, 2022, 2023 and 2024.

SEC source: 0001567619-20-001294 · doc1.xml · nonDerivative · entry 1

Boucher Brent J. · CIK 0001766229 · SVP and GM of Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,906

F1 · shares: The exempt disposition of 490 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on January 17, 2018.

SEC source: 0001567619-19-023485 · doc1.xml · nonDerivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,422

F1 · shares: The exempt disposition of 736 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on December 18, 2017.

SEC source: 0001567619-19-020025 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 260,418

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.15 to $14.22, inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1.

SEC source: 0001567619-19-019773 · doc1.xml · derivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,139

Underlying: Common Stock · 50,139 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited.

F1 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited.

F1 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-19-019769 · doc1.xml · derivative · entry 1

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,195

Underlying: Common Stock · 6,195 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited.

F1 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited.

F1 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-19-019778 · doc1.xml · derivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,357

Underlying: Common Stock · 8,357 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited.

F1 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited.

F1 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-19-019776 · doc1.xml · derivative · entry 1

Greiner Michael · CIK 0001520392 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,320

Underlying: Common Stock · 15,320 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited.

F1 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited.

F1 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-19-019771 · doc1.xml · derivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,945

Underlying: Common Stock · 6,945 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited.

F1 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited.

F1 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-19-019767 · doc1.xml · derivative · entry 1

Boucher Brent J. · CIK 0001766229 · SVP and GM of Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,452

Underlying: Common Stock · 6,452 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited.

F1 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited.

F1 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-19-017367 · doc1.xml · nonDerivative · entry 1

Greiner Michael · CIK 0001520392 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,438

F1 · shares: The exempt disposition of 826 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on August 18, 2016.

SEC source: 0001567619-19-016192 · doc1.xml · derivative · entry 3

JOHNSON WESLEY · CIK 0001258791 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,650 shares

Expires 2019-08-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Options for 25% of the shares each became exercisable on 08/07/2013, 08/07/2014, 08/07/2015 and 08/07/2016, respectively.

SEC source: 0001567619-19-016192 · doc1.xml · nonDerivative · entry 2

JOHNSON WESLEY · CIK 0001258791 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,088

SEC source: 0001567619-19-016192 · doc1.xml · nonDerivative · entry 1

JOHNSON WESLEY · CIK 0001258791 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,669

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-19-015724 · doc1.xml · nonDerivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,558

F2 · shares: The exempt disposition of 1,752 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 27, 2016.

SEC source: 0001567619-19-015722 · doc1.xml · nonDerivative · entry 2

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,928

F2 · shares: The exempt disposition of 252 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 27, 2016.

SEC source: 0001567619-19-015718 · doc1.xml · nonDerivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,723

F3 · shares: The exempt disposition of 285 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 27, 2016.

SEC source: 0001567619-19-015724 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 143,310

F1 · shares: The exempt disposition of 1,826 shares of common stock of AngioDynamics, Inc. ("Common Stock") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 26, 2017.

SEC source: 0001567619-19-015720 · doc1.xml · nonDerivative · entry 1

Simpson Robert Arthur · CIK 0001706163 · SVP/GM, Global Vascular

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,441

F1 · shares: The exempt disposition of 309 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 26, 2017.

SEC source: 0001567619-19-015722 · doc1.xml · nonDerivative · entry 1

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,180

F1 · shares: The exempt disposition of 276 shares of common stock of AngioDynamics, Inc. ("Common Stock") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 26, 2017.

SEC source: 0001567619-19-015718 · doc1.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,008

F2 · shares: The exempt disposition of 306 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 26, 2017.

SEC source: 0001567619-19-015712 · doc1.xml · nonDerivative · entry 1

Greiner Michael · CIK 0001520392 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,304

F1 · shares: The exempt disposition of 511 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 26, 2017.

SEC source: 0001567619-19-015205 · doc1.xml · nonDerivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,669

F3 · shares: The exempt disposition of 355 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 22, 2015.

SEC source: 0001567619-19-015718 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,314

F1 · shares: The exempt disposition of 355 shares of common stock of AngioDynamics, Inc. ("Common Stock") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 22, 2015.

SEC source: 0001567619-19-015209 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,136

F1 · shares: The exempt disposition of 1,444 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-19-015207 · doc1.xml · nonDerivative · entry 2

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,456

F2 · shares: The exempt disposition of 74 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-19-015207 · doc1.xml · nonDerivative · entry 1

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,530

F1 · shares: The exempt disposition of 218 shares of common stock of AngioDynamics, Inc. ("Common Stock") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-19-015211 · doc1.xml · nonDerivative · entry 2

Greiner Michael · CIK 0001520392 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,815

F2 · shares: The exempt disposition of 172 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-19-015211 · doc1.xml · nonDerivative · entry 1

Greiner Michael · CIK 0001520392 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,987

F1 · shares: The exempt disposition of 404 shares of common stock of AngioDynamics, Inc. ("Common Stock") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-19-015205 · doc1.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,024

F2 · shares: The exempt disposition of 148 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-19-015205 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,172

F1 · shares: The exempt disposition of 241 shares of common stock of AngioDynamics, Inc. ("Common Stock") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-19-015203 · doc1.xml · nonDerivative · entry 2

Boucher Brent J. · CIK 0001766229 · SVP and GM of Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,396

F2 · shares: The exempt disposition of 148 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-19-015203 · doc1.xml · nonDerivative · entry 1

Boucher Brent J. · CIK 0001766229 · SVP and GM of Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,544

F1 · shares: The exempt disposition of 225 shares of common stock of AngioDynamics, Inc. ("Common Stock") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-19-015199 · doc1.xml · nonDerivative · entry 2

Simpson Robert Arthur · CIK 0001706163 · SVP/GM, Global Vascular

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,750

F2 · shares: The exempt disposition of 148 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-19-015199 · doc1.xml · nonDerivative · entry 1

Simpson Robert Arthur · CIK 0001706163 · SVP/GM, Global Vascular

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,898

F1 · shares: The exempt disposition of 244 shares of common stock of AngioDynamics, Inc. ("Common Stock") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-19-015201 · doc1.xml · nonDerivative · entry 2

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,158

F2 · shares: The exempt disposition of 172 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-19-015201 · doc1.xml · nonDerivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,330

F1 · shares: The exempt disposition of 233 shares of common stock of AngioDynamics, Inc. ("Common Stock") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-19-015033 · doc1.xml · nonDerivative · entry 1

GOLD JEFFREY · CIK 0000938659 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,640

F1 · shares: The acquisition of 7,057 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 7,057 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/17/2020.

SEC source: 0001567619-19-015037 · doc1.xml · nonDerivative · entry 1

REED JAN STERN · CIK 0001124181 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,656

F1 · shares: The acquisition of 7,057 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 7,057 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/17/2020.

SEC source: 0001567619-19-015039 · doc1.xml · derivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,967

Underlying: Common Stock · 83,967 shares

Expires 2029-07-17

F2 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 17, 2020, such that 25% of the options will vest on each of July 17, 2020, 2021, 2022 and 2023.

SEC source: 0001567619-19-015039 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,580

F1 · shares: This acquisition of 25,104 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 25,104 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 17, 2020, such that 25% of the restricted stock units will vest on each of July 17, 2020, 2021, 2022 and 2023.

SEC source: 0001567619-19-015025 · doc1.xml · nonDerivative · entry 1

DONNELLY HOWARD W · CIK 0001212978 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,546

F1 · shares: The acquisition of 7,057 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 7,057 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/17/2020.

SEC source: 0001567619-19-015027 · doc1.xml · nonDerivative · entry 1

Auen Eileen O'Shea · CIK 0001428073 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,340

F1 · shares: The acquisition of 7,057 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 7,057 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/17/2020.

SEC source: 0001567619-19-015031 · doc1.xml · nonDerivative · entry 1

Gould Kevin J · CIK 0001504093 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,181

F1 · shares: The acquisition of 7,057 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 7,057 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/17/2020.

SEC source: 0001567619-19-015055 · doc1.xml · nonDerivative · entry 1

Licitra Karen A · CIK 0001754757 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,057

F1 · shares: The acquisition of 7,057 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 7,057 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/17/2020.

SEC source: 0001567619-19-015029 · doc1.xml · nonDerivative · entry 1

Meteny Dennis S · CIK 0001289336 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,078

F1 · shares: The acquisition of 7,057 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 7,057 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/17/2020.

SEC source: 0001567619-19-015035 · doc1.xml · nonDerivative · entry 1

JOHNSON WESLEY · CIK 0001258791 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,019

F1 · shares: The acquisition of 7,057 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 7,057 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/17/2020.